AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10617941 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA-rich meal
Number of subjects: 32
Study 10617941 — intervention group
Group type: COMPARATOR
Intervention: Combined groups (SFA and MUFA-rich meals)
Number of subjects: 32
Study 9188930 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% mequitazine eye-drops, four times daily for 5 days
Number of subjects: 20
Study 9188930 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 20
Study 8166477 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by aggressive randomized chemotherapy and PCI
Number of subjects: 186
Study 8166477 — intervention group
Group type: COMPARATOR
Intervention: Preoperative (neoadjuvant) chemotherapy followed by surgery
Number of subjects: 186
Study 31344268 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal pre-pregnancy BMI
Number of subjects: 201
Study 31344268 — intervention group
Group type: EXPERIMENTAL
Intervention: Child lean body mass
Number of subjects: 201
Study 31344268 — intervention group
Group type: COMPARATOR
Intervention: Gestational diabetes, pre-pregnancy BMI, child body fat percentage
Number of subjects: 201
Study 29064536 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilatation (FMD)
Number of subjects: 90
Study 29064536 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Number of subjects: 90
Study 29064536 — intervention group
Group type: COMPARATOR
Intervention: No-therapy
Number of subjects: 90
Study 27236388 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching attachment behaviors to pregnant women (six educational sessions lasting 60-90 minutes)
Number of subjects: 190
Study 27236388 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 190
Study 27236388 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching attachment behaviors to pregnant women
Number of subjects: 190
Study 26214039 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue vaccine
Number of subjects: 35165
Study 26214039 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35165
Study 22917554 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil (6 μg/breath, 3 to 9 breaths, 4 times/day)
Number of subjects: 29
Study 22917554 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil
Number of subjects: 29
Study 20477784 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target effect-site concentration of 6.0 microgxml(‐1)
Number of subjects: 400
Study 20477784 — intervention group
Group type: COMPARATOR
Intervention: Propofol target effect-site concentrations of 0 and 3.0 microgxml(‐1)
Number of subjects: 400
Study 17923329 — intervention group
Group type: EXPERIMENTAL
Intervention: private verbal emotional disclosure
Number of subjects: 98
Study 17923329 — intervention group
Group type: EXPERIMENTAL
Intervention: clinician-assisted verbal emotional disclosure
Number of subjects: 98
Study 17923329 — intervention group
Group type: COMPARATOR
Intervention: arthritis information control
Number of subjects: 98
Study 17923329 — intervention group
Group type: COMPARATOR
Intervention: no-treatment, standard care only control
Number of subjects: 98
Study 15906109 — intervention group
Group type: EXPERIMENTAL
Intervention: Native sodium hyaluronate (group I)
Number of subjects: 40
Study 15906109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross‐linked hylan G‐F 20 (group II)
Number of subjects: 40
Study 11817922 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention over 10 weeks
Number of subjects: 98
Study 11817922 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention
Number of subjects: 98
Study 11817922 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 98
Study 11817922 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 10516734 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Number of subjects: 223
Study 10516734 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 223
Study 10516734 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 223
Study 10516734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 9041079 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical interferon alpha 2b (IFN‐alpha) 5 x 10(6) IU/ml, four times daily for 4 weeks
Number of subjects: 31
Study 9041079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9041079 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical interferon alpha 2b (IFN‐alpha) for patients with correction > 5.00 D
Number of subjects: 31
Study 9041079 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical interferon alpha 2b (IFN‐alpha)
Number of subjects: 31
Study 1552999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 1-alpha-hydroxyvitamin D3 (1 alpha‐OH‐D3) after each dialysis at increasing doses up to 4 micrograms, with Mg(OH)2 as sole phosphate binder.
Number of subjects: 47
Study 1552999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 1-alpha-hydroxyvitamin D3 (1 alpha‐OH‐D3) with Mg(OH)2 as sole phosphate binder.
Number of subjects: 47
Study 1552999 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO3) as phosphate binder.
Number of subjects: 47
Study 3991397 — intervention group
Group type: EXPERIMENTAL
Intervention: Diumide K (frusemide 40 mg, potassium 8 mmol)
Number of subjects: 28
Study 3991397 — intervention group
Group type: EXPERIMENTAL
Intervention: Burinex K (bumetanide 0.5 mg, potassium 7.7 mmol)
Number of subjects: 28
Study 3991397 — intervention group
Group type: COMPARATOR
Intervention: Frusemide
Number of subjects: 28
Study 3991397 — intervention group
Group type: COMPARATOR
Intervention: Bumetanide
Number of subjects: 28
Study 31858429 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide + rituximab (R2)
Number of subjects: 36
Study 31858429 — intervention group
Group type: COMPARATOR
Intervention: Rituximab + placebo (R-placebo)
Number of subjects: 36
Study 29626369 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 20
Study 29626369 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 20
Study 27407058 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Number of subjects: 87
Study 27407058 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 87
Study 25347304 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational clips featuring Hispanic traditions and words
Number of subjects: 259
Study 25347304 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational clips featuring Chinese traditions and words
Number of subjects: 259
Study 25347304 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational clips featuring characters (Hispanic, Chinese American, Anglo)
Number of subjects: 259
Study 22268900 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic therapy (two 15-min sessions per week for 8 weeks) targeting words from semantic categories (animals, food, clothes)
Number of subjects: 15
Study 22268900 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (no therapy in Phase 1)
Number of subjects: 15
Study 22268900 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effect of therapy over the two groups
Number of subjects: 15
Study 22268900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-therapy TAWF scores
Number of subjects: 15
Study 22268900 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-therapy TAWF scores
Number of subjects: 15
Study 20625396 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 145
Study 20625396 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide in Arg389Arg genotype
Number of subjects: 145
Study 20625396 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide in Arg389Gly genotype
Number of subjects: 145
Study 20625396 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide in Gly389Gly genotype
Number of subjects: 145
Study 20625396 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide in Arg389Gly-Ser49Gly genotype
Number of subjects: 145
Study 20625396 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate during atrial fibrillation in Arg389Arg genotype
Number of subjects: 145
Study 20625396 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate during atrial fibrillation in Arg389Gly genotype
Number of subjects: 145
Study 20625396 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate during atrial fibrillation in Gly389Gly genotype
Number of subjects: 145
Study 20625396 — intervention group
Group type: EXPERIMENTAL
Intervention: Arg389Gly-Ser49Gly genotype prevalence
Number of subjects: 145
Study 18805105 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham risk score (FRS) low risk group (FRS <10%)
Number of subjects: 498
Study 18805105 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham risk score (FRS) intermediate risk group (FRS 10% to 20%)
Number of subjects: 498
Study 18805105 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham risk score (FRS) high risk group (FRS >20%)
Number of subjects: 498
Study 18805105 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with atherosclerosis in the low risk group
Number of subjects: 498
Study 15682364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic stress myocardial perfusion imaging (adenosine or dipyridamole)
Number of subjects: 93
Study 15682364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic stress myocardial perfusion imaging
Number of subjects: 93
Study 15682364 — intervention group
Group type: COMPARATOR
Intervention: Clinical score
Number of subjects: 93
Study 11919132 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg pramlintide q.i.d.
Number of subjects: 480
Study 11919132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 11919132 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 or 60 microg pramlintide q.i.d. (open-label extension)
Number of subjects: 480
Study 10450297 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH dietary pattern
Number of subjects: 459
Study 10450297 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 459
Study 7562730 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 percent neutral NaF solution rinsed once a week
Number of subjects: 1640
Study 7562730 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2 mg NaF tablet chewed, rinsed, and swallowed daily
Number of subjects: 1640
Study 7562730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures (mouthrinse and tablet)
Number of subjects: 1640
Study 7562730 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride treatment)
Number of subjects: 1640
Study 1287559 — intervention group
Group type: COMPARATOR
Intervention: CORN oil infant formula
Number of subjects: 0
Study 1287559 — intervention group
Group type: COMPARATOR
Intervention: SOY oil infant formula
Number of subjects: 0
Study 1287559 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (HM)
Number of subjects: 0
Study 4073086 — intervention group
Group type: EXPERIMENTAL
Intervention: ticarcillin plus clavulanic acid
Number of subjects: 90
Study 4073086 — intervention group
Group type: COMPARATOR
Intervention: cefoxitin
Number of subjects: 90
Study 4073086 — intervention group
Group type: COMPARATOR
Intervention: tobramycin plus piperacillin
Number of subjects: 90
Study 31341122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental treatment (DT) perceived as a cause of OMLs
Number of subjects: 280
Study 31341122 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture placement
Number of subjects: 280
Study 31341122 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant treatment
Number of subjects: 280
Study 31341122 — intervention group
Group type: COMPARATOR
Intervention: Chief complaint site (CC)
Number of subjects: 280
Study 30570869 — intervention group
Group type: EXPERIMENTAL
Intervention: NBASS‐APS pain management model
Number of subjects: 228
Study 30570869 — intervention group
Group type: COMPARATOR
Intervention: C‐APS (customary APS)
Number of subjects: 228
Study 27010770 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,064-nm LPNY laser (Group A: 0.3 ms pulse duration, 5 mm spot size, 16 J/cm2 fluence, 10 Hz frequency)
Number of subjects: 13
Study 27010770 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,064-nm LPNY laser (Group B: 0.6 ms pulse duration, 2 mm spot size, 225 J/cm2 fluence, 5 Hz frequency)
Number of subjects: 13
Study 27010770 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,064-nm LPNY laser (both groups)
Number of subjects: 13
Study 24033222 — intervention group
Group type: EXPERIMENTAL
Intervention: Causally rich information
Number of subjects: 56
Study 24033222 — intervention group
Group type: EXPERIMENTAL
Intervention: Causally weak information
Number of subjects: 56
Study 24033222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangible reward
Number of subjects: 56
Study 24033222 — intervention group
Group type: COMPARATOR
Intervention: No reward (baseline condition)
Number of subjects: 56
Study 22374555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 290
Study 22374555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A plus zinc (AZ group)
Number of subjects: 290
Study 22374555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A combined with multiple micronutrients (AMM group)
Number of subjects: 290
Study 20374670 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation therapy, provided weekly for 4 months followed by monthly sessions for 4 months.
Number of subjects: 1
Study 17493183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 1 g intramuscularly every 24 hours
Number of subjects: 69
Study 17493183 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 1 g intramuscularly every 24 hours
Number of subjects: 69
Study 17493183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 69
Study 17493183 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 69
Study 17493183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime and Ceftriaxone
Number of subjects: 69
Study 16198825 — intervention group
Group type: EXPERIMENTAL
Intervention: High b‐value diffusion imaging (q‐space imaging)
Number of subjects: 15
Study 16198825 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 15
Study 11995875 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive surgical zipper (Medizip)
Number of subjects: 120
Study 11995875 — intervention group
Group type: COMPARATOR
Intervention: Intracutaneous sutures
Number of subjects: 120
Study 10365924 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg/day
Number of subjects: 0
Study 10365924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7572690 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4444
Study 7572690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study 2248837 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 1 mg kg‐1 i.m.
Number of subjects: 60
Study 2248837 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram kg‐1 i.v.
Number of subjects: 60
Study 2248837 — intervention group
Group type: COMPARATOR
Intervention: No analgesic (placebo)
Number of subjects: 60
Study 471153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticrynafen (TCNF)
Number of subjects: 25
Study 471153 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 25
Study 30680830 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + RDN
Number of subjects: 387
Study 30680830 — intervention group
Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 387
Study 30680830 — intervention group
Group type: EXPERIMENTAL
Intervention: RDN
Number of subjects: 387
Study 28236299 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Efficacy Score (PEscore)
Number of subjects: 1592
Study 25873334 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi group (n = 71)
Number of subjects: 142
Study 25873334 — intervention group
Group type: COMPARATOR
Intervention: Routine exercise group (n = 71)
Number of subjects: 142
Study 24193288 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable fibrin sealant patch (AFSP)
Number of subjects: 346
Study 24193288 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical treatment (ST)
Number of subjects: 346
Study 24193288 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable fibrin sealant patch (AFSP) and Standard surgical treatment (ST)
Number of subjects: 346
Study 21391017 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years parent and child training programs
Number of subjects: 99
Study 19214861 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064 nm Nd:YAG laser treatment (fluence 30 J/cm, 18 mm spot size, dynamic cooling device pulse duration of 30 ms)
Number of subjects: 12
Study 17202429 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder
Number of subjects: 0
Study 17202429 — intervention group
Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 0
Study 14765876 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric cell saver used to collect autologous blood
Number of subjects: 22
Study 14765876 — intervention group
Group type: COMPARATOR
Intervention: Banked homologous blood transfusion
Number of subjects: 22
Study 14765876 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric cell saver
Number of subjects: 22
Study 11913309 — intervention group
Group type: EXPERIMENTAL
Intervention: AHDC chewing gum (5% sodium bicarbonate), 2 tablets for 20 minutes, 2 times daily
Number of subjects: 28
Study 11913309 — intervention group
Group type: COMPARATOR
Intervention: Mint tablet (sugarless), 2 tablets for 20 minutes, 2 times daily
Number of subjects: 28
Study 9477866 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 10
Study 9477866 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 10
Study 7701191 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (300 mg daily)
Number of subjects: 50
Study 7701191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3588258 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant oxygen therapy for 48 hours
Number of subjects: 39
Study 3588258 — intervention group
Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 39
Study 29283132 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fenofibrate 160 mg/day
Number of subjects: 50
Study 29283132 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment protocol (Control Group B)
Number of subjects: 50
Study 28814275 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose monotherapy (S-1 30 mg/m2 twice daily days 1-14 every 3 weeks, followed by second line irinotecan 250-350 mg/m2 iv day 1 every 3 weeks or 180-250 mg/m2 iv day 1 every 2 weeks)
Number of subjects: 150
Study 28814275 — intervention group
Group type: COMPARATOR
Intervention: Reduced dose combination therapy (S-1 20 mg/m2 days 1-14 + oxaliplatin 100 mg/m2 iv day 1 every 3 weeks, followed by second line S-1 20 mg/m2 days 1-14 + irinotecan 180 mg/m2 day 1 every 3 weeks)
Number of subjects: 150
Study 26316345 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg BID
Number of subjects: 1000
Study 26316345 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1000
Study 23292524 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine treatment for myopia
Number of subjects: 35
Study 23292524 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 35
Study 23292524 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Hz flicker response amplitude
Number of subjects: 35
Study 23292524 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal data
Number of subjects: 35
Study 20921118 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 121
Study 20921118 — intervention group
Group type: COMPARATOR
Intervention: Adolescent-focused individual therapy (AFT)
Number of subjects: 121
Study 19078912 — intervention group
Group type: EXPERIMENTAL
Intervention: Early walking and compression stockings (Group B)
Number of subjects: 219
Study 19078912 — intervention group
Group type: COMPARATOR
Intervention: 5 days of bed rest (Group A)
Number of subjects: 219
Study 16883916 — intervention group
Group type: EXPERIMENTAL
Intervention: Haoqin Qingdan Decoction (HQD) and prednisone
Number of subjects: 120
Study 16883916 — intervention group
Group type: COMPARATOR
Intervention: Prednisone and cyclophosphamide (CTX)
Number of subjects: 120
Study 12832308 — intervention group
Group type: EXPERIMENTAL
Intervention: Group visits
Number of subjects: 120
Study 12832308 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 11122757 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0
Study 11122757 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 8867520 — intervention group
Group type: EXPERIMENTAL
Intervention: terguride (1 mg b.i.d.)
Number of subjects: 20
Study 8867520 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 8867520 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa (250 mg p.o.)
Number of subjects: 20
Study 1638712 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5-20 mg/day)
Number of subjects: 56
Study 1638712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 6396439 — intervention group
Group type: EXPERIMENTAL
Intervention: Home intermittent peritoneal dialysis (IPD)
Number of subjects: 114
Study 6396439 — intervention group
Group type: COMPARATOR
Intervention: Home hemodialysis (HD)
Number of subjects: 114
Study 30362216 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous catheter drainage (PCD)
Number of subjects: 190
Study 30362216 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous needle aspiration (PNA)
Number of subjects: 190
Study 28960596 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress (depressive symptoms)
Number of subjects: 14577